Pelvic Pain and the Use of Extracorporeal Shock Wave Therapy (ESWT)

Review Article | Vol 5 | Issue 2 |  July-December 2025 | page: 39-41 | Romina Tang Candiotti

DOI: https://doi.org/10.13107/jrs.2025.v05.i02.181

Open Access License: CC BY-NC 4.0

Copyright Statement: Copyright © 2025; The Author(s).

Submitted Date: 25 Oct 2025, Review Date: 12 Nov 2025, Accepted Date: Nov 2025 & Published: 30 Dec 2025

Author: Romina Tang Candiotti [1]

[1] Pelvic floor unit. RENOVA MEDIC Medical Center, Lima, Perú.

Address of Correspondence
Armando Tonatiuh Ávila García,
Pelvic floor unit. RENOVA MEDIC Medical Center, Lima, Perú.
E-mail: romi.arw@gmail.com

Abstract

Chronic pelvic pain (CPP) is a heterogeneous condition affecting individuals of both sexes and may originate from urological, gynecological, gastroenterological, musculoskeletal, and neurological structures. Over the past three years (2023–2025), multiple clinical studies, reviews, and meta-analyses have evaluated the use of focused extracorporeal shock waves treatment (ESWT), low-intensity shock waves (Li-ESWT) and radial pressure waves (RPW), on specific CPP subtypes, particularly chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), pelvic floor myofascial pain, and vulvodynia/vestibulodynia. Recent evidence suggests benefits in pain reduction and functional improvement in the short and medium term, with a favorable safety profile; however, methodological limitations and protocol heterogeneity persist.
Keywords: Chronic pelvic pain syndrome, Shock waves, Pelvic floor myofascial pain, Chronic prostatitis, Vulvodynia, Vestibulodynia.

References:

1. Skaudickas D, Lenčiauskas P, Skaudickas A, Undžytė G. Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome: Long-term follow-up. Open Med (Wars). 2023 Oct 28;18(1):20230832. doi: 10.1515/med-2023-0832. PMID: 37900960; PMCID: PMC10612526.
2. Hur KJ, Bae WJ, Ha US, Kim S, Piao J, Jeon KH, et al. Safety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study. Prostate Int. 2024 Dec;12(4):195-200. doi: 10.1016/j.prnil.2024.06.003. Epub 2024 Jun 13. PMID: 39735201; PMCID: PMC11681323. Wang YR. Safety of low-intensity extracorporeal shock wave therapy — 2024. Revisión en PMC.
3. Huang N, Qin Z, Sun W, Bao K, Zha J, Zhang P, et al. Comparing the effectiveness of extracorporeal shockwave therapy and myofascial release therapy in chronic pelvic pain syndrome: study protocol for a randomized controlled trial. Trials. 2023 Oct 18;24(1):675. doi: 10.1186/s13063-023-07633-1. PMID: 37853420; PMCID: PMC10583345.
4. Wang YR, Feng B, Qi WB, Gong YW, Kong XB, Cheng H, Dong ZL, Tian JQ, Wang ZP. Safety of low-intensity extracorporeal shock wave therapy in prostate disorders: in vitro and in vivo evidence. Asian J Androl. 2024 Sep 1;26(5):535-543. doi: 10.4103/aja202448. Epub 2024 Aug 6. PMID: 39107962; PMCID: PMC11449405.
5. Labetov I, Vaganova A, Kovalev G, Shkarupa D. Extracorporeal shockwave therapy in treatment of chronic prostatitis/chronic pelvic pain syndrome: Systematic review and meta-analyses. Neurourol Urodyn. 2024 Nov;43(8):1924-1937. doi: 10.1002/nau.25524. Epub 2024 Jun 7. PMID: 38847290. Hegazy M. A randomized trial on low-intensity shockwave therapy (2024) — publicación en revista científica (Nature-linked).
6. Hegazy M, Sheir KZ, Gaballah MA, Elshal AM. A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):305-311. doi: 10.1038/s41391-024-00820-4. Epub 2024 Mar 29. PMID: 38553627; PMCID: PMC11096095.
7. Ogbeivor C, AlMubarak H, Akomolafe T, Alkahtani H, AlMugizel H, Marin I, Aldosari H, Aldhwayan N, Mohamed G, Alobthani K. The effectiveness of radial shockwave therapy on myofascial pain syndrome: a two-armed, randomized double-blind placebo-controlled trial. BMC Musculoskelet Disord. 2025 Apr 24;26(1):413. doi: 10.1186/s12891-025-08659-z. PMID: 40275291; PMCID: PMC12023603.
8. Hurt K, Svestkova O, Halaska M, Driak D, Rakovicova I, Musalek M, Krajcova A. Extracorporeal Shock Wave Therapy of Vulvodynia: A Feasibility Study. Actual Gyn. 2019;11:18-22

[Article Text HTML]       [Full Text PDF]